CoreCivic (CXW) Q3 2026 Earnings Call Transcript

CoreCivic reported Q3 2026 adjusted diluted EPS of $0.49, up 104% year over year, and adjusted EBITDA of $117.8 million, up 33%; results exceeded analyst estimates by $0.06 per share and $2.7 million, respectively. It sold four detention facilities to the Department of Homeland Security for $2.2 billion gross ($1.6 billion net after tax), repaid more than $700 million of debt, and initiated a $500 million accelerated share repurchase. The company raised 2026 adjusted EPS guidance to $1.74–$1.80 and normalized FFO guidance to $2.78–$2.85, while noting that further facility sales to ICE remain preliminary and uncertain.

Analysis

The key valuation question is whether CXW has converted politically exposed property value into durable per-share cash flow—or sold assets while retaining operating obligations on less favorable terms. Debt reduction and the ASR lower interest and share count, but buybacks only compound value if the remaining business can sustain earnings after contract amendments at the sold sites. The near-term EPS uplift therefore deserves a quality-of-earnings discount until those terms are disclosed.

Over 1–3 months, the main catalysts are the final ASR settlement, Appleton’s initial population ramp, and clarity on modified contracts. Appleton adds capacity but is not automatically high-margin: recently activated sites are still below mature operating margins, so population growth may precede meaningful earnings conversion. Additional facility sales are upside optionality, not a base-case catalyst; counting proceeds before agreement would overstate value.

Over 6–18 months, CSP offers a modest diversification path, but distribution investment and the earn-out compete with repurchases for capital. The larger structural risk is customer and policy concentration: multiyear funding improves visibility, not certainty of contracted utilization or renewal beyond that window. A shift to alternative capacity, appropriations changes, or weaker enforcement could impair utilization and the valuation multiple simultaneously. Conversely, constrained government capacity could support activation demand and replacement-value arguments—but sale prices are not proof of the value of the continuing management contracts.

Contrarian point: the strong quarter may obscure flat residential margins and the transition costs of ramping facilities. Verify contract economics, operating margins by activated site, and the 2027 EBITDA bridge in filings; the transcript itself contains inconsistent facility-count references.

Key Decisions for Investors

• Consider a modest, staged long in CXW rather than chasing the earnings reaction; add only if subsequent disclosures show that adjusted earnings convert to cash after maintenance/activation capex and modified-contract economics. No price target is supportable from the supplied data.
• Treat additional ICE asset sales as optionality, not underwriting. Reassess only after definitive terms disclose proceeds, retained management fees/per diems, and any transition obligations.
• Track Appleton’s ramp and mature-site margin progression into the February 2027 outlook. Falsify the earnings-conversion thesis if populations rise but residential margins or EBITDA guidance weaken, or if activation costs materially exceed the stated plan.
• Keep political/funding risk explicit in position sizing: a change in appropriations, contract utilization, or federal detention strategy is a downside catalyst even if near-term funding visibility remains intact. Confirm contract modifications and guidance assumptions against the company’s SEC filings before adding.